Nyxoah's ACCCESS U.S. Pivotal Study Meets Primary Safety and Efficacy Endpoints
Nyxoah Announces ACCCESS U.S. Pivotal Study Meets Primary Safety and Efficacy Endpoints in Complete Concentric Collapse PatientsReports an Apnea-Hypopnea Index (AHI) responder rate of 77.2% on a Full Analysis Set basis
Nyxoah's sleep-apnea treatment passed its big safety test, showing it helps most patients breathe better at night. When a company's medicine works as hoped in its main test, it's a sign the company might move forward and grow.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.